(CIDRAP News) Although antiviral drugs were used to treat many seriously sick people during the H1N1 influenza pandemic, experts at a conference today said they could have been used more widely and that some opportunities to learn from their use were missed.
(CIDRAP News) The nation is reaching a new milestone in its fight against pandemic flu, with the number of vaccine doses expected to reach 100 million by the end of the week and nearly half of states opening up immunization to anyone who wants it, federal officials said today.
(CIDRAP News) – The era of cell-based influenza vaccine production in the United States seemed to move closer today as Novartis unveiled its new, nearly billion-dollar manufacturing plant in Holly Springs, N.C., but onshore production and marketing of cell-based vaccines remains a few years away.
(CIDRAP News) The head of the Centers for Disease Control and Prevention (CDC) predicted today that the current wave of H1N1 influenza is likely to begin to wane before the shortage of vaccine for it eases.
Dr. Thomas Frieden made the comment at a wide-ranging US House subcommittee session that aired the reasons for and impact of the vaccine delays and the prospects for avoiding a repeat of the problem. The session was streamed over the Web.
(CIDRAP News) Interim clinical trial findings announced today affirm that children younger than 10 need two pandemic H1N1 vaccine doses, and initial findings in pregnant women reveal no safety concerns and a need for only one dose.
Federal officials also detailed the role of an independent panel of experts to review vaccine safety data and released a report outlining the government's vaccine safety monitoring system.
(CIDRAP News) In advance of the expected pandemic H1N1 vaccination campaign this fall, the US Department of Health and Human Services (HHS) yesterday invited the media to join federal officials in a tabletop exercise to prepare for some possible communications challenges.
(CIDRAP News) – Federal health officials today said the first results of novel H1N1 vaccine trials—needed for determining the number and size of doses people will get—are expected in mid-September.
Two trials in adult and elderly volunteers started Aug 7 and are now almost fully enrolled, said Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), at a press teleconference.